At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 286 enrolled
Drug / intervention
Lebrikizumab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Lebrikizumab When Used in Combination With Topical Corticosteroid Treatment in Japanese Patients With Moderate-to-Severe Atopic Dermatitis
In Brief
A Phase 3 clinical trial evaluating Lebrikizumab, Placebo, and 1 other intervention for Dermatitis, Atopic and 4 related conditions. Completed, enrolled 286 participants across 37 sites.
Detailed Summary
The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in combination with a topical corticosteroids in Japanese participants with atopic dermatitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDermatitis, Atopic, Dermatitis, Eczema, Skin Diseases, Skin Diseases, Genetic
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedFeb 2021
Enrollment StartMar 2021
Primary CompletionJul 2022
Study CompletionFeb 2023
TodayJul 2026
First PostedFeb 18, 2021
Enrollment StartMar 10, 2021
Primary CompletionJul 31, 2022
Study CompletionFeb 1, 2023
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 5.4 years ago
Interventions
Lebrikizumabdrug
Administered SC
Placebodrug
Administered SC
Topical Corticosteroiddrug
Self-applied